CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DALKR1275QPredictiveSupportsSensitivity/ResponseNeuroblastomaCrizotinibBresler et al., 2011
DFGFR3::BAIAP2L1FusionPredictiveSupportsSensitivity/ResponseBladder CarcinomaPD173074Wu et al., 2013
DNPM1EXON 11 MUTATIONPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaTretinoin,NSC348884Balusu et al., 2011
DNPM1W288FSPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaNSC348884Balusu et al., 2011
ENPM1W288FSPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaDaunorubicin,Cytarabine,EtoposideFalini et al., 2005
DTSC1Frameshift TruncationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaSirolimusLiang et al., 2010
BTSC1Loss-of-functionPredictiveSupportsSensitivity/ResponseBladder CarcinomaEverolimusIyer et al., 2012
BIDH1R132PrognosticDoes Not SupportAcute Myeloid LeukemiaSchnittger et al., 2010
BWT1Exon 7 MutationPrognosticDoes Not SupportAcute Myeloid LeukemiaGaidzik et al., 2009
BCEBPAMutationPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaBurnett et al., 2010
BCEBPAMutationPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaFröhling et al., 2004
BCEBPAN-TERMINAL FRAME SHIFTPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaFröhling et al., 2004
BDNMT3AR882PrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaGaidzik et al., 2013
BFLT3TKD MUTATIONPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaBacher et al., 2008
BNPM1EXON 11 MUTATIONPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaSchlenk et al., 2009
BNPM1EXON 11 MUTATIONPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaThiede et al., 2006
BNPM1EXON 11 MUTATIONPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaFalini et al., 2005
BNPM1EXON 11 MUTATIONPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaBüchner et al., 2009
BNPM1EXON 11 MUTATIONPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaGaidzik et al., 2012
BNPM1EXON 11 MUTATIONPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaSchlenk et al., 2008
BNPM1EXON 11 MUTATIONPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaDöhner et al., 2005
BDNMT3AR882PrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaRibeiro et al., 2012
BDNMT3AMutationPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaRibeiro et al., 2012
BDNMT3AR882PrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaRibeiro et al., 2012
AFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaPort et al., 2014
DKRASG12/G13PrognosticSupportsPoor OutcomeColorectal CancerLièvre et al., 2008
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaLinch et al., 2014
BNPM1EXON 11 MUTATIONPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaTian et al., 2014
BWT1Exon 7 MutationPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaGaidzik et al., 2009
BWT1Exon 7 MutationPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaPaschka et al., 2008
BWT1Exon 7 MutationPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaVirappane et al., 2008
BWT1Exon 7 MutationPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaVirappane et al., 2008
BWT1Exon 9 MutationPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaPaschka et al., 2008
BFLT3TKD MUTATIONDiagnosticDoes Not SupportPositiveAcute Myeloid LeukemiaYamamoto et al., 2001
BKRASG12DiagnosticDoes Not SupportPositiveLung Non-small Cell CarcinomaRiely et al., 2008
DCCND2PROMOTER DEMETHYLATIONDiagnosticSupportsNegativeStomach CancerOshimo et al., 2003
BFLT3ITDDiagnosticSupportsPositiveAcute Myeloid LeukemiaYamamoto et al., 2001
BIDH1R132CDiagnosticSupportsPositiveAcute Myeloid LeukemiaAbbas et al., 2010
BKRASG12DDiagnosticSupportsPositiveLung CancerDogan et al., 2012
BEGFRL858RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinib,GefitinibLim et al., 2014
DAKT1E17KPredictiveDoes Not SupportSensitivity/ResponseBreast CancerAkt Inhibitor MK2206Beaver et al., 2013
DBCR::ABL1FusionPredictiveSupportsResistanceAcute Myeloid LeukemiaImatinibNimmanapalli et al., 2002
BEGFRT790MPredictiveSupportsResistanceLung Non-small Cell CarcinomaGefitinibKobayashi et al., 2005
DESR1L536QPredictiveSupportsResistanceBreast CancerHormone TherapyToy et al., 2013
DESR1D538GPredictiveSupportsResistanceBreast CancerHormone TherapyToy et al., 2013
DESR1Y537CPredictiveSupportsResistanceBreast CancerHormone TherapyToy et al., 2013
DESR1Y537NPredictiveSupportsResistanceBreast CancerHormone TherapyToy et al., 2013
DESR1Y537SPredictiveSupportsResistanceBreast CancerHormone TherapyToy et al., 2013
DKITV654APredictiveSupportsResistanceGastrointestinal Stromal TumorImatinibHeinrich et al., 2006
BKRASExon 2 MutationPredictiveSupportsResistanceColorectal CancerCetuximabLièvre et al., 2006
Page 27 of 96
PreviousNext